Figure S5. Cooperative and antagonistic combination strategies with BLU-222. A, BLISS synergistic analysis for antagonism between BLU-222 and CHK1 checkpoint kinase inhibitors in MDA-MB-231 cells (n = 3 per group; BLISS scores calculated with SynergyFinder v3). B, Live cell proliferative monitoring of the indicated cell lines treated with BLU-222, palbociclib, or in combination (n = 3–4 per group; one-way ANOVA; error bars represent SEM). C, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with either 500 nM BLU-222, palbociclib, or combination. D, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with siCCNE1, siCCND1 or combination. E, Live-cell imaging endpoint stills for HCC-1806 cells treated for 5 days with 500 nM BLU-222, palbociclib, or combination (scale bar = 100 µm). ns, not significant; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.